Phuong Dao

2.2k total citations · 1 hit paper
7 papers, 1.3k citations indexed

About

Phuong Dao is a scholar working on Pathology and Forensic Medicine, Genetics and Neurology. According to data from OpenAlex, Phuong Dao has authored 7 papers receiving a total of 1.3k indexed citations (citations by other indexed papers that have themselves been cited), including 4 papers in Pathology and Forensic Medicine, 3 papers in Genetics and 2 papers in Neurology. Recurrent topics in Phuong Dao's work include Lymphoma Diagnosis and Treatment (4 papers), Chronic Lymphocytic Leukemia Research (3 papers) and T-cell and B-cell Immunology (2 papers). Phuong Dao is often cited by papers focused on Lymphoma Diagnosis and Treatment (4 papers), Chronic Lymphocytic Leukemia Research (3 papers) and T-cell and B-cell Immunology (2 papers). Phuong Dao collaborates with scholars based in United States and Lithuania. Phuong Dao's co-authors include Linas Mažutis, Alexander Y. Rudensky, Dana Pe’er, Kristy Choi, Krishna Kadaveru, Ruby Wasti, Andrew Cornish, Manu Setty, Sandhya Prabhakaran and George Plitas and has published in prestigious journals such as Cell, Blood and Immunity.

In The Last Decade

Phuong Dao

5 papers receiving 1.3k citations

Hit Papers

Single-Cell Map of Diverse Immune Phenotypes in the Breas... 2018 2026 2020 2023 2018 400 800 1.2k

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Phuong Dao United States 3 739 656 643 293 120 7 1.3k
Ruby Wasti France 2 707 1.0× 656 1.0× 621 1.0× 292 1.0× 121 1.0× 2 1.3k
Daphne Tsoucas United States 8 565 0.8× 602 0.9× 575 0.9× 249 0.8× 103 0.9× 8 1.2k
Zemin Zhang China 12 627 0.8× 559 0.9× 612 1.0× 298 1.0× 203 1.7× 23 1.3k
Ayse Bassez Belgium 4 659 0.9× 815 1.2× 842 1.3× 462 1.6× 255 2.1× 8 1.5k
Giorgia Maroni Italy 5 667 0.9× 512 0.8× 460 0.7× 148 0.5× 141 1.2× 7 1.1k
Hye Hyeon Eum South Korea 9 289 0.4× 839 1.3× 460 0.7× 516 1.8× 117 1.0× 13 1.2k
Pedro Corrêa de Sampaio United States 11 418 0.6× 558 0.9× 837 1.3× 434 1.5× 80 0.7× 12 1.3k
Woosung Chung South Korea 6 287 0.4× 875 1.3× 483 0.8× 553 1.9× 147 1.2× 8 1.2k
Satyen H. Gohil United Kingdom 14 278 0.4× 546 0.8× 343 0.5× 226 0.8× 60 0.5× 30 966
François Lassailly United Kingdom 12 303 0.4× 683 1.0× 419 0.7× 170 0.6× 95 0.8× 17 1.3k

Countries citing papers authored by Phuong Dao

Since Specialization
Citations

This map shows the geographic impact of Phuong Dao's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Phuong Dao with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Phuong Dao more than expected).

Fields of papers citing papers by Phuong Dao

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Phuong Dao. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Phuong Dao. The network helps show where Phuong Dao may publish in the future.

Co-authorship network of co-authors of Phuong Dao

This figure shows the co-authorship network connecting the top 25 collaborators of Phuong Dao. A scholar is included among the top collaborators of Phuong Dao based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Phuong Dao. Phuong Dao is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

7 of 7 papers shown
1.
Buege, Michael J., Esther Drill, Steven M. Horwitz, et al.. (2023). Low incidence of cardiotoxicity in patients with non‐Hodgkin lymphoma receiving EPOCH after prior anthracycline exposure. European Journal Of Haematology. 111(1). 96–102.
2.
Qualls, David, Michael J. Buege, Phuong Dao, et al.. (2022). Tafasitamab and Lenalidomide in Relapsed/Refractory Large B Cell Lymphoma (R/R LBCL): Real World Outcomes in a Multicenter Retrospective Study. Blood. 140(Supplement 1). 787–789. 16 indexed citations
3.
Buege, Michael J., Phuong Dao, Philip Caron, et al.. (2021). Successful implementation of outpatient R ± DHAX (rituximab, dexamethasone, oxaliplatin, cytarabine) for select patients with lymphoma: a single-center experience. Leukemia & lymphoma. 63(4). 876–884. 1 indexed citations
4.
Buege, Michael J., et al.. (2021). IVAC With or Without Rituximab for Relapsed or Refractory B-Cell Non-Hodgkin Lymphomas: Real-World Experience in the Modern Era. Clinical Lymphoma Myeloma & Leukemia. 21(12). 873–878. 1 indexed citations
5.
Buege, Michael J., et al.. (2020). IVAC +/- R for Relapsed or Refractory B-Cell Non-Hodgkin Lymphomas: Real-World Experience in the Modern Era. Blood. 136(Supplement 1). 10–10.
6.
Veeken, Joris van der, Yi Zhong, Roshan Sharma, et al.. (2019). Natural Genetic Variation Reveals Key Features of Epigenetic and Transcriptional Memory in Virus-Specific CD8 T Cells. Immunity. 50(5). 1202–1217.e7. 37 indexed citations
7.
Azizi, Elham, Ambrose Carr, George Plitas, et al.. (2018). Single-Cell Map of Diverse Immune Phenotypes in the Breast Tumor Microenvironment. Cell. 174(5). 1293–1308.e36. 1250 indexed citations breakdown →

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026